GlassScriptPhysician profile
Richard David Lee
NPI 1285625236
$5,654.38
in general payments reported to CMS, 2019-2025
26 companies · $957 in 2025
The $957 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $179 · 2021: $543 · 2022: $2,235 · 2023: $631 · 2024: $866 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,967.37 | 2022 | |
| Abbvie INC. | $1,304.09 | 2019-2025 | |
| Pfizer INC. | $696.29 | 2019-2025 | |
| Exact Sciences Corporation | $196.26 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Eisai INC. | $170.77 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $145.19 | 2021 | |
| Lilly USA, LLC | $136.17 | 2024-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.93 | 2019-2024 | Xifaxan |
| Carlsmed, INC. | $107.57 | 2024 | Aprevo |
| Axsome Therapeutics, INC. | $101.85 | 2023 | Sunosi |
| Idorsia Pharmaceuticals US INC | $100.86 | 2022-2025 | Quviviq, Quviviq |
| Amgen INC. | $94.26 | 2020-2024 | Repatha, Otezla |
| Vertical Pharmaceuticals, LLC | $85.95 | 2019 | |
| Antares Pharma, INC. | $67.40 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.64 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $56.05 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $47.46 | 2024-2025 | NP Thyroid 60 |
| Ascend Therapeutics US, LLC | $31.36 | 2021-2024 | |
| Tolmar, INC. | $28.03 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $23.77 | 2022 | |
| Novo Nordisk INC | $22.46 | 2025 | Wegovy |
| Allergan, INC. | $21.48 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.34 | 2025 | |
| Merck Sharp & Dohme LLC | $20.89 | 2022 | |
| Acerus Pharmaceuticals Corporation | $16.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.